Skip to main content
      RT @hausmannMD: Honored to have our article "Using questions to enhance #rheumatology education" featured in the Medical

      Jonathan Hausmann MD hausmannMD

      4 years ago
      Honored to have our article "Using questions to enhance #rheumatology education" featured in the Medical Education Year in Review by @LisaCriscione at #ACR20. Read the full article here --> https://t.co/iDVvaxrTl5 #MedEd #rheum https://t.co/y78BP2qkqM
      RT @MeralElRamahiMD: Check out this session at 4 pm EST today on “Psoriatic Arthritis: Treatment in Practice” detail

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      Check out this session at 4 pm EST today on “Psoriatic Arthritis: Treatment in Practice” detailing emerging therapies and co-management strategies by this amazing team! #ACR20 @RheumNow https://t.co/baNtDLe6Rc
      RT @drdavidliew: Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors?
      C

      David Liew drdavidliew

      4 years ago
      Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors? Can we learn lessons about collaborative work from @rheum_covid? Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy
      RT @drdavidliew: Inflammation is not a single entity, and the imperative to dissect it carefully is so great in irAEs -

      David Liew drdavidliew

      4 years ago
      Inflammation is not a single entity, and the imperative to dissect it carefully is so great in irAEs - in both treatment and measurement. "I'm attempting to stir the pot" - @LCalabreseDO - and there really is plenty to think about. https://t.co/8C6RbMI2l9
      RT @drdavidliew: One of my #ACR20 highlights about to start - irAE Study Group, hosted by @CCalabreseDO & @NohaMDAnd

      David Liew drdavidliew

      4 years ago
      One of my #ACR20 highlights about to start - irAE Study Group, hosted by @CCalabreseDO & @NohaMDAnderson Imminent paradigm definition by @LCalabreseDO: one of the biggest challenges in the field: how to target therapies in irAEs, to maintain cancer response #ACR2020 @RheumNow https://t.co/WzFbCc8TuT
      RT @drdavidliew: Just the beginning... trained over 1397 x-rays, this will only get better.

      It could either:
      - stop hum

      David Liew drdavidliew

      4 years ago
      Just the beginning... trained over 1397 x-rays, this will only get better. It could either: - stop humans from having to do tedious things - make Sharp/SvdH scores readily available in clinical practice/developing world/consistent in studies. Either way, good! tag @DrCMcMaster
      RT @doctorRBC: Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clin

      Robert B Chao, MD doctorRBC

      4 years ago
      Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update. Beautiful organization of targeted therapy in multiple autoimmune diseases. Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J
      RT @doctorRBC: Dr. Siri will see you now...🤖
      Machine learning identified 9 signatures including nail pso, CRP and 7 b

      Robert B Chao, MD doctorRBC

      4 years ago
      Dr. Siri will see you now...🤖 Machine learning identified 9 signatures including nail pso, CRP and 7 biomarkers to distinguish PsA from PsO pts without arthritis and will help diagnose PsA early. ➡️will need to test independent data @RheumNow #ACR20 Abs#0502
      RT @MeralElRamahiMD: Abst#0194 at #ACR20 showed that significant symptoms of depression in RA are more frequent than dep

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      Abst#0194 at #ACR20 showed that significant symptoms of depression in RA are more frequent than depression diagnosed clinically, suggesting that depression may go undiagnosed and that symptoms of depression predicted mortality in RA patients! @RheumNow https://t.co/GqwXNB45y2
      RT @LCalabreseDO: Totally down by this but...
      what to do about about SSZ??? ( I don't use it anymore but the data are

      Leonard Calabrese LCalabreseDO

      4 years ago
      Totally down by this but... what to do about about SSZ??? ( I don't use it anymore but the data are weird).... @philipcrobinson @JYazdanyMD @EBRheum @alhkim @CCalabreseDO https://t.co/kYNxxjqL2B
      RT @sclerodermaUM: Please join #ACR20 for late breaking abstract on Ziritaxestat, selective autotaxin inhibitor. Phase

      Dr. Dinesh Khanna sclerodermaUM

      4 years ago
      Please join #ACR20 for late breaking abstract on Ziritaxestat, selective autotaxin inhibitor. Phase 2a trial with stats significant effect on skin score and well tolerated. @UMIntMed Session Date Monday, November 9 Presentation Time: 12:15 PM - 12:30 PM ET
      RT @StefanSiebert1: Our paper on body composition in #PsoriaticArthritis #PsA is now published in @RheumJnl

      Results sh

      Stefan Siebert StefanSiebert1

      4 years ago
      Our paper on body composition in #PsoriaticArthritis #PsA is now published in @RheumJnl Results show increased visceral fat in PsA similar to type 2 diabetes in @uk_biobank Important implications for management. @iiiglasgow @UofGICAMS @AMRAMedical https://t.co/6vfkz78tzC
      RT @ErinTay61017977: BSR Guidelines and best practice is the top member benefit and reason for joining @RheumatologyUK.

      Erin Taylor ErinTay61017977

      4 years ago
      BSR Guidelines and best practice is the top member benefit and reason for joining @RheumatologyUK. For anyone who wants to know more about how to get involved with guideline development, this is the perfect opportunity. #MemberEngagement https://t.co/SbskxCzkmI
      ×